drugset / Trial / NCT02632994

Master Rollover Protocol for Continued Safety Assessment of Study Drug

NCT02632994

Expanded access Available Eli Lilly and Company

Summary

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject LOXO-260 Unknown Oral
Subject LOXO-338 Small molecule Oral
Subject LY2503029 Unknown Oral
Subject Samotolisib Small molecule Oral

Indications